Zetia/Zocor combo is Vytorin
Executive Summary
Merck and Schering-Plough choose Vytorin as the brand name for the fixed-dose ezetimibe/simvastatin combination. Companies filed for approval of Zetia/Zocor for cholesterol reduction in July 2003; the user fee deadline is Sept. 24, 2004. Zetia was approved in 2002 for use as monotherapy and in combination with Zocor (1"The Pink Sheet" Nov. 4, 2002, p. 5)...
You may also be interested in...
Merck/Schering Vytorin (correction)
User fee date for Merck/Schering-Plough's Vyortin (ezetimibe/simvastatin) is July 24. "The Pink Sheet" incorrectly reported the date (1"The Pink Sheet" March 15, 2004, In Brief)...
Schering/Merck Zetia Clears FDA; Price Favors Combo With Low-Dose Zocor
Merck and Schering-Plough are pricing Zetia so that combination use with Zocor 10 mg is attractive compared to high-dose Zocor monotherapy
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.